Skip to main content
  • CSA Medical Inc.
  • Investment: 2024
  • Lexington, Massachusetts
  • Status: Active

CSA Medical is advancing care for COPD patients with chronic bronchitis by harnessing the power of liquid nitrogen spray cryotherapy. Through its RejuvenAir® System, an innovative, investigational device, the company aims to target the overproduction of mucus and damaged cilia within the airways, addressing the underlying causes of chronic bronchitis. By destroying these damaged cells without causing scar tissue, RejuvenAir® is designed to promote the rapid regrowth of healthy, functioning cells in the lung. CSA Medical is dedicated to improving outcomes and enhancing the quality of life for patients suffering from chronic bronchitis through its pioneering cryotherapy technology.

Involved Team

Dr. Luc Marengère
Managing Partner

Wendelin Maners (CEO)